Overview
TLSA market data
Price History
TLSA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.17 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.29 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.87 – $2.60 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $124.5 · P/B 19.57.
Company News
Tiziana Life Sciences shares are trading higher after the company announced quantitative PET imaging results from the third patient with Multiple System Atrophy in the Phase 2 clinical trial treated with intranasal foralumab to complete dosing.Benzinga · Jul 31, 2026, 1:54 PM
Tiziana Life Sciences Announces Quantitative PET Imaging Results From Third Patient With Multiple System Atrophy In Its Phase 2 Clinical Trial Treated With Intranasal Foralumab To Complete Dosing; Scans Demonstrated Reductions In Inflammatory ActivityBenzinga · Jul 31, 2026, 11:07 AM
Tiziana Life Sciences shares are trading higher after the company announced its executive chairman bought 42,357 shares.Benzinga · Jul 22, 2026, 1:05 PM
Tiziana Life Sciences Executive Chairman Gabriele Cerrone Buys 42,357 Shares At $0.99 Per Share, Bringing Total Holding To 44,814,587 Shares, 34.93% Of Issued Share CapitalBenzinga · Jul 22, 2026, 11:05 AM
Tiziana Announces Last Patient In Ongoing Phase 2a Clinical Trial Receives First Dose Of Intranasal Foralumab For Treatment Of Non-Active Secondary Progressive Multiple Sclerosis; Topline Data Expected In Late Q3/Early Q4 Of 2026Benzinga · Jun 25, 2026, 11:10 AM
Tiziana Life Sciences Says Its Executive Chairman And Founder, Gabriele Cerrone, Increases Holdings With Purchase Of 15,000 Common Shares At $1.11 Per ShareBenzinga · Jun 15, 2026, 11:15 AM
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis TrialGlobenewswire Inc · May 21, 2026, 3:15 PM
Tiziana Life Sciences Completes Enrollment In Phase 2a Trial Of Intranasal Foralumab For Secondary Progressive Multiple Sclerosis, With Topline Data Expected In Q3 2026Benzinga · May 21, 2026, 3:10 PM
Tiziana Life Sciences' Updated Data From Its Ongoing Expanded Access Program Of Intranasal Foralumab For Non-Active Secondary Progressive Multiple Sclerosis Shows Encouraging Trends In Stabilization Of Disability And Meaningful Improvements In FatigueBenzinga · May 19, 2026, 11:10 AM
Tiziana Life Sciences Announces Initial Quantitative PET Imaging Results From The First Two Patients With Multiple System Atrophy In Its Phase 2 Clinical Trial Of ForlumabBenzinga · May 14, 2026, 11:20 AM